Eli Lilly’s weight-loss franchise delivered over $10 billion in combined quarterly revenue through its tirzepatide drugs—Mounjaro for type 2 diabetes and Zepbound for obesity. That haul propelled overall top-line growth into double-digit percentages, outpacing most large-cap pharmaceutical peers. High demand led to episodic supply constraints until Lilly expanded four additional manufacturing lines in Indianapolis and Kinsale, Ireland, enabling capacity to more than double year-over-year.

Lilly filed for FDA approval of orforglipron at the end of last year, positioning it as the first oral GLP-1/glucagon receptor dual agonist without food-intake restrictions. Phase 3 data showed average patient weight loss of 15 percent over 24 weeks, comparable to leading injectable competitors but with the convenience of a once-daily tablet. Analysts forecast the pill could capture up to 30 percent of the obesity-drug market within two years of launch, driving annual peak sales above $5 billion.

Industry projections estimate the global obesity-drug market will near $100 billion by 2030, up from approximately $25 billion today. Lilly’s aggressive infrastructure investments and proven drug efficacy have already lifted its market share to roughly 40 percent of combined injectable sales. With orforglipron’s potential approval expected mid-year, revenue from Lilly’s weight-loss portfolio could grow at a compound annual rate exceeding 25 percent through 2026, supporting the thesis that next year will mark its breakout period.